NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (“Salona Global” or the “Company”) (TSXV:SGMD) today posted financial results for the second quarter of 2023, ending June 30, 2023, and provided an update on its turn-around plan.
During the second quarter, the Company acquired Biodex Medical Systems, Inc. (“Biodex”), pushing revenue to $16.6 million for the three months ended June 30, 2023. The Company reported negative Adjusted EBITDA (defined below) of $819,394 for the same period.
On June 13, 2023, Michael Seckler was appointed CEO of the Company by the board of directors with a mandate to generate organic revenue growth and achieve enterprise profitability. In the time since his appointment Mr. Seckler has taken several steps to achieve this goal including:
These actions to improve efficiency began in the second quarter and have continued in the current quarter. Mr. Seckler and the entire company are laser focused on delivering positive Adjusted EBITDA beginning with the third quarter.
“I have worked with alacrity in the past 45 days to turn this business around,” said Mike Seckler, CEO of Salona Global. “I have been pleased at how quickly the organization implemented my cost cutting plan. It has given us the ability to demonstrate cash generation from our business rather than cash burn. Because of this, we have been able restructure our debt and provide space to make further investments in revenue growth through future product launches and tuning up our sales and marketing divisions.”
“To be clear, I didn’t come to Salona Global simply to implement cost cuts. This Company has some compelling new product opportunities to fill some major voids in the physical therapy market. I want to give credit to the previous management team for acquiring these companies and assets. It gives me a large revenue base to implement a turnaround plan, but also a basis for high margin profitable growth going forward.”
“The new Salona Global is built for both profit and revenue growth,” continued Mr. Seckler. “We have four new exciting Biodex products we are planning to launch. Two products will be designed to provide unique solutions and reduce costs of our therapist customers using artificial intelligence. We also have a renewed focus on leveraging our sales and marketing presence globally, a particular strength of mine given my background as head of global marketing with Ferring Pharmaceuticals. I look forward to meeting with investors and market participants in next month to explain our new products, growth plans and international sales initiatives for the near future, as well as results from our current plan to generate profits from our existing business.”
The Company previously issued calendar 2023 projections for revenues, gross margin and Adjusted EBITDA. The new management team is conducting a strategic review of the entire business as of July 1, 2023 and given the losses from the first six months of the year under the previous management team, the new team expects, therefore, to revise downward the expectations for Adjusted EBITA.
Full Financial Statements
Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss and Unaudited Interim Condensed Consolidated Balance Sheets are included below. The full financial statements for the three and six months ended June 30, 2023 and related management discussion and analysis (in the form of Quarterly Report on Form 10-Q) was filed on August 14, 2023 with the United States Securities and Exchange Commission and is available at www.sec.gov, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca.
For more information please contact:
Mike Seckler
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Non-GAAP Measures
This press release refers to "Adjusted EBITDA" which is a non-GAAP and non-IFRS financial measure that does not have a standardized meaning prescribed by GAAP or IFRS. The Company’s presentation of this financial measure may not be comparable to similarly titled measures used by other companies. This non-GAAP financial measure assists the Company’s management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition plans that are fundamentally different from the ongoing operating plans of the Company. The Company’s management also believes that presenting this measure allows investors to view the Company’s performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
“Adjusted EBITDA” is defined as net loss excluding interest expense, provision for income taxes, depreciation of property and equipment, amortization of right-of-use asset, amortization of intangible asset, foreign exchange (loss) gain, other income, provision for impairment, change in fair value of contingent consideration, transaction costs, and stock-based compensation.
The following table provides reconciliation between net income (loss) and Adjusted EBITDA:
| 3 months ended June 30, | 6 months ended June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net Loss | $ | (1,115,843 | ) | $ | (3,650,333 | ) | $ | (2,778,587 | ) | $ | (4,243,967 | ) | ||||
| Interest Expense | 454,446 | 114,763 | 732,532 | 235,217 | ||||||||||||
| Provision for income taxes | 2,294 | (31,607 | ) | 38,544 | (145,717 | ) | ||||||||||
| Depreciation of property and equipment | 265,066 | 71,817 | 449,330 | 140,940 | ||||||||||||
| Amortization of right-of-use asset | 540,308 | 83,611 | 922,141 | 170,036 | ||||||||||||
| Amortization of intangible asset | 350,553 | 249,029 | 701,099 | 464,010 | ||||||||||||
| Foreign exchange (loss) gain | (2,990 | ) | (240 | ) | (4,518 | ) | 3,933 | |||||||||
| Other income | (815,428 | ) | (3 | ) | (815,561 | ) | (48 | ) | ||||||||
| Provision for impairment | - | 7,391 | - | 5,527,913 | ||||||||||||
| Change in fair value of earnout consideration | (1,165,697 | ) | 2,451,600 | (1,165,697 | ) | 2,451,600 | ||||||||||
| Change in fair value of contingent consideration | 77,795 | 459,693 | 273,095 | (5,394,008 | ) | |||||||||||
| Transaction costs | 75,541 | 369,289 | 534,312 | 1,568,409 | ||||||||||||
| Severance Expenses | 122,989 | - | 229,089 | - | ||||||||||||
| Stock based compensation | 391,572 | 489,089 | 737,096 | 927,658 | ||||||||||||
| Adjusted EBITDA | $ | (819,394 | ) | $ | 614,099 | $ | (147,125 | ) | $ | 1,705,976 | ||||||
Additional Information
Unless otherwise specified, all dollar amounts in this press release are expressed in Canadian dollars.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this press release constitute "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. These statements can be identified by the use of forward-looking terminology such as “expects” “believes”, “estimates”, "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", and "anticipate", and similar expressions as they relate to the Company, including: annualized operating expense reductions and; and the Company planning to launch four new Biodex products.
All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including: the Company is able to maintain reduced levels of personnel and expenses; and the Company is able to successfully execute on the activities required to launch four new Biodex products. Salona cautions that the forward-looking statements contained herein are qualified by important factors that could cause actual results to differ materially from those reflected by such statements. Such factors include but are not limited to the general business and economic conditions in the regions in which Salona operates; the ability of Salona to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; ongoing or new disruptions in the supply chain, the extent and scope of such supply chain disruptions, and the timing or extent of the resolution or improvement of such disruptions; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on Salona’ s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which Salona is exposed; the failure of third parties to comply with their obligations to Salona or its affiliates; the impact of new and changes to, or application of, current laws and regulations; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by Salona; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with United States Securities and Exchange Commission and available at www.sec.gov, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
| SALONA GLOBAL MEDICAL DEVICE CORPORATION | ||||||||||||||||
| Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
| 3 months ended | 3 months ended | 6 months ended | 6 months ended | |||||||||||||
| June 30 | June 30 | June 30 | June 30 | |||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue | $ | 16,575,075 | $ | 9,761,145 | $ | 27,258,304 | $ | 18,429,560 | ||||||||
| Cost of revenue: | ||||||||||||||||
| Direct service personnel | 1,652,004 | 1,443,458 | 3,477,759 | 2,874,397 | ||||||||||||
| Direct material costs | 8,964,709 | 4,837,017 | 13,390,800 | 8,552,625 | ||||||||||||
| Other direct costs | 325,947 | 204,513 | 661,471 | 499,521 | ||||||||||||
| Total cost of revenue | 10,942,660 | 6,484,988 | 17,530,030 | 11,926,543 | ||||||||||||
| Gross margin | 5,632,415 | 3,276,157 | 9,728,274 | 6,503,017 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 6,966,370 | 3,151,147 | 10,841,584 | 5,724,699 | ||||||||||||
| Depreciation of property and equipment | 265,066 | 71,817 | 449,330 | 140,940 | ||||||||||||
| Amortization of right-of-use assets | 540,308 | 83,611 | 922,141 | 170,036 | ||||||||||||
| Amortization of intangible assets | 350,553 | 249,029 | 701,099 | 464,010 | ||||||||||||
| Total operating expenses | 8,122,297 | 3,555,604 | 12,914,154 | 6,499,685 | ||||||||||||
| Net operating (loss) gain | (2,489,882 | ) | (279,447 | ) | (3,185,880 | ) | 3,332 | |||||||||
| Interest expense | (454,446 | ) | (114,763 | ) | (732,532 | ) | (235,217 | ) | ||||||||
| Foreign currency exchange gain (loss) | 2,990 | 240 | 4,518 | (3,933 | ) | |||||||||||
| Other income | 815,428 | 3 | 815,561 | 48 | ||||||||||||
| Provision for impairment | - | (7,391 | ) | - | (5,527,913 | ) | ||||||||||
| Change in fair value of earnout consideration | 1,165,697 | (2,451,600 | ) | 1,165,697 | (2,451,600 | ) | ||||||||||
| Change in fair value of contingent consideration | (77,795 | ) | (459,693 | ) | (273,095 | ) | 5,394,008 | |||||||||
| Transaction costs | (75,541 | ) | (369,289 | ) | (534,312 | ) | (1,568,409 | ) | ||||||||
| Net loss before taxes | (1,113,549 | ) | (3,681,940 | ) | (2,740,043 | ) | (4,389,684 | ) | ||||||||
| Provision for income taxes | (2,294 | ) | 31,607 | (38,544 | ) | 145,717 | ||||||||||
| Net loss | $ | (1,115,843 | ) | $ | (3,650,333 | ) | $ | (2,778,587 | ) | $ | (4,243,967 | ) | ||||
| Other comprehensive loss | ||||||||||||||||
| Foreign currency translation gain (loss) | 104,993 | (28,965 | ) | 62,550 | 668,004 | |||||||||||
| Comprehensive (loss) | $ | (1,010,850 | ) | $ | (3,679,298 | ) | $ | (2,716,037 | ) | $ | (3,575,963 | ) | ||||
| Net loss per share | ||||||||||||||||
| Basic and diluted | $ | (0.02 | ) | $ | (0.07 | ) | $ | (0.04 | ) | $ | (0.08 | ) | ||||
| Weighted average number of common stock and Class A shares outstanding | 73,949,654 | 52,882,328 | 68,178,999 | 50,742,334 | ||||||||||||
| SALONA GLOBAL MEDICAL DEVICE CORPORATION | ||||||||
| Unaudited Interim Condensed Consolidated Balance Sheets | ||||||||
| June 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 1,398,103 | $ | 1,928,464 | ||||
| Accounts receivable, net | 10,980,119 | 6,353,275 | ||||||
| Inventories, net | 13,348,620 | 8,102,626 | ||||||
| Prepaid expenses and other receivables | 1,811,923 | 216,489 | ||||||
| Total current assets | 27,538,765 | 16,600,854 | ||||||
| Security deposit | 595,857 | 566,198 | ||||||
| Long-term accounts receivable | 141,668 | 189,616 | ||||||
| Long-term prepaid expenses and other receivables | 436,614 | 441,025 | ||||||
| Property and equipment, net | 3,942,998 | 3,399,898 | ||||||
| Right-of-use assets, net | 11,668,572 | 7,781,300 | ||||||
| Intangible assets, net | 10,584,239 | 9,376,162 | ||||||
| Goodwill | 15,251,230 | 13,695,194 | ||||||
| Total assets | $ | 70,159,943 | $ | 52,050,247 | ||||
| Liabilities and stockholders' equity | ||||||||
| Liabilities | ||||||||
| Line of credit | $ | 8,434,492 | $ | 5,162,711 | ||||
| Accounts payable and accrued liabilities | 10,097,527 | 6,641,181 | ||||||
| Current portion of debt | 9,033,918 | 195,489 | ||||||
| Current portion of lease liability | 1,565,326 | 847,253 | ||||||
| Other liabilities | 4,013,413 | 1,807,702 | ||||||
| Obligation for payment of earnout consideration | 12,729,714 | 15,506,531 | ||||||
| Total current liabilities | 45,874,390 | 30,160,867 | ||||||
| Debt, net of current portion | 741,238 | 574,515 | ||||||
| Lease liability, net of current portion | 7,726,691 | 5,983,333 | ||||||
| Total liabilities | $ | 54,342,319 | $ | 36,718,715 | ||||
| Stockholders' equity | ||||||||
| Common stock; no par value, unlimited shares authorized; 56,423,092 shares issued and outstanding as of June 30, 2023 (December 31, 2022: 53,707,780) | 39,610,457 | 38,767,442 | ||||||
| Class A shares; no par value, unlimited shares authorized; 21,378,799 shares issued and outstanding as of June 30, 2023 (December 31, 2022: 3,403,925) | 12,542,088 | 1,800,064 | ||||||
| Common stock to be issued: 368,500 shares to be issued as of June 30, 2023 (December 31, 2022: nil) | 103,180 | - | ||||||
| Class A Shares to be issued: 6,261,340 Class A shares to be issued as of June 30, 2023 (December 31, 2022: 19,019,000) | 4,696,005 | 14,264,250 | ||||||
| Additional paid-in-capital | 9,154,765 | 8,072,610 | ||||||
| Accumulated other comprehensive income | 1,751,002 | 1,688,452 | ||||||
| Deficit | (52,039,873 | ) | (49,261,286 | ) | ||||
| Total stockholders' equity | 15,817,624 | 15,331,532 | ||||||
| Total liabilities and stockholders' equity | $ | 70,159,943 | $ | 52,050,247 | ||||
| Last Trade: | C$0.13 |
| Daily Volume: | 0 |
| Market Cap: | C$7.480M |
November 25, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
